Skip to main content
Chong Kun Dang Pharmaceutical Corp. logo

Chong Kun Dang Pharmaceutical Corp. — Investor Relations & Filings

Ticker · 185750 ISIN · KR7185750007 KO Manufacturing
Open in API
Filings indexed 424 across all filing types
Latest filing 2026-06-01 Governance Information
Country KR South Korea
Listing KO 185750

About Chong Kun Dang Pharmaceutical Corp.

https://www.ckdpharm.com

Chong Kun Dang Pharmaceutical Corp. is a pharmaceutical company focused on the research, development, manufacturing, and commercialization of a broad range of medicines. Its portfolio encompasses prescription drugs, over-the-counter (OTC) products, and health supplements. The company is committed to innovation, with significant investment in R&D to develop novel treatments. Key therapeutic areas of focus include systemic anti-infectives and metabolic diseases. Through a robust pipeline and extensive clinical trials, the company develops quality medicines to improve public health and quality of life.

Recent filings

Filing Released Lang Actions
기업지배구조보고서공시
Governance Information Classification · 95% confidence The document is a detailed corporate governance report (“기업지배구조보고서”) covering governance policies, board composition, shareholder meeting practices, compliance with governance indicators, and internal control structures. It is not merely an announcement or a proxy statement but a substantive governance report. This matches the Governance Information category (CGR).
2026-06-01 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 95% confidence The document is a Korean “주식등의 대량보유상황보고서,” i.e., a large shareholding report filed by Kopernik Global Investors, LLC to the Financial Services Commission and Korea Exchange, detailing the number of shares held, percentage ownership, changes over time, and reasons for the holdings. This corresponds to a major shareholding notification of crossing thresholds and changes in significant ownership levels.
2026-06-01 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is a Korean “분기보고서 (제 14 기) 2026년 01월 01일~2026년 03월 31일,” containing detailed company overview, business content, full financial statements (연결재무제표, 재무제표), management’s discussion, audit opinions, and other substantive financial and operational information for a quarter. This aligns precisely with an Interim/Quarterly Report, not merely an announcement or summary. Therefore, the correct classification is IR. Q1 2026
2026-05-15 Korean
투자판단관련주요경영사항 (고혈압 치료제로 개발중인 CKD339의 식약처(MFDS) 제3상 임상시험 계획 승인 신청)
Regulatory Filings Classification · 79% confidence The document is a Korean stock exchange disclosure titled "투자판단 관련 주요경영사항" (Material Event for Investment Decisions) describing the company’s application for MFDS Phase III clinical trial approval. It is not a financial report or earnings release but a regulatory announcement of a material corporate event. Therefore it falls under the general Regulatory Filings (RNS) category.
2026-05-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' which translates to 'Report on Large Shareholding Status'. It contains detailed information about share ownership percentages, changes in shareholdings, relationships between shareholders, and contractual details related to shareholdings. The document references specific dates and legal provisions related to capital markets and financial investment laws. There is no indication that this is an annual report, earnings release, or any other financial statement. Instead, it is a notification/report about significant share ownership and changes thereof, which aligns with the definition of 'Major Shareholding Notification (MRQ)'. The document length is sufficient and contains substantive data, not just an announcement or certification. Therefore, the correct classification is MRQ with high confidence.
2026-04-30 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 90% confidence The document is a summary table of provisional (잠정) quarterly business results for Q1 2026 (영업(잠정)실적), including key metrics like sales, operating profit, and net income, presented under fair disclosure rules. It provides initial highlights of the period’s financial performance, not a full interim report or annual filing. This aligns with an Earnings Release (ER). Q1 2026
2026-04-29 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.